MicroCare Acquires Certol International: Expands Products and Services

MicroCare, LLC a global supplier of critical cleaning fluids and materials used in the electronics, medical device manufacturing, fiber optic and metal finishing markets announced today that it has acquired Certol International, a Denver, Colorado based manufacturer of specialty cleaning and disinfecting products to the medical, dental, and consumer marketplaces.

“We are very excited to announce this acquisition.  Certol has a 40-year history of providing EPA registered high performance surface disinfectants and specialty cleaners engineered for use.

in dental offices, medical offices, and hospital settings. Certol also manufactures specialty products used in industrial, marine and consumer cleaning applications,” said Tom Tattersall, Chief Executive Officer at MicroCare.

“We believe that the Certol product lines, customer relationships, and centralized U.S. location will reinforce our position as a leading supplier to the industries we serve, and will allow us to more efficiently deliver an expanded range of complementary solutions to our customers.  With this acquisition, MicroCare will continue to be well-situated to capitalize on the many emerging trends in the dental and medical markets.  We view this important acquisition as an excellent step to position the business for continued growth as we work with customers to solve their cleaning and disinfecting challenges.”

Certol International

This acquisition is aligned with the MicroCare strategic goals and priorities, namely, to fuel growth through the delivery of innovative, value-added solutions and services into the global critical cleaning industry.  The Certol leading product and development initiatives will amplify the already strong programs in the MicroCare pipeline and will enable continued focus on high growth segments, such as automotive, medical, electronics and fiber optic communications.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”